Announcement on Approval by the US FDA of the Formulation Product Micafungin Sodium for Injection of the Wholly-owned Subsidiary

About this update from Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

Announcement on Approval by the US FDA of the Formulation Product Micafungin Sodium for Injection of the Wholly-owned Subsidiary The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Zhejiang Hisun Pharmaceutical Co., Ltd. Class A